Entwine Bio
Entwine Bio integrates large-scale perturbative RNA splicing data with advanced computational models to drive cancer-specific neoantigen stimulation and enhance anti-tumor immunity. Their approach aims to reveal actionable mechanisms for stimulating the anti-tumor immune response.
Entwine Bio
Entwine Bio integrates large-scale perturbative RNA splicing data with advanced computational models to drive cancer-specific neoantigen stimulation and enhance anti-tumor immunity. Their approach aims to reveal actionable mechanisms for stimulating the anti-tumor immune response.
TL;DR
Focus: AI-driven control of RNA splicing to stimulate cancer-specific neoantigens
Founded: May 19, 2022
Headquarters: San Francisco, California, United States
Stage: Pre-Seed (Jun 2022)
Total funding: $1,400,000 (USD)
Founders: Colin McNally; Mona Khalaj
Company Overview
Problem Domain
Cancer immunotherapy; neoantigen discovery through RNA splicing modulation.
Founded
2022
Industry
Biotechnology
Funding Track Record
Pre-Seed round recorded/announced on 2022-06-01.